NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)
December 06, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the potential of NGM707 in combination with KEYTRUDA for the treatment of patients with advanced or...
NGM Bio to Participate in Upcoming Investor Conferences
November 09, 2021 06:30 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Presented preliminary Phase 1a/1b trial findings at ESMO 2021 for NGM120, a GFRAL antagonist antibody product candidate, that showed the drug was well tolerated in advanced solid tumors and provided...
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
September 16, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1a/1b study...
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research
August 23, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
Publication describes NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of the tumor stromaILT3-fibronectin interactions within the tumor microenvironment may form a stromal...
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a...
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
July 22, 2021 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blindness, with no currently approved treatmentsNGM621 is a monoclonal antibody against complement C3, a...
NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors
July 07, 2021 07:00 ET
|
NGM Biopharmaceuticals, Inc.
--NGM707, a ILT2/ILT4 dual antagonistic antibody, is engineered to reverse myeloid suppression with the goal of improving patient immune responses to tumors-- --Study to evaluate potential of NGM707...
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases
July 01, 2021 07:00 ET
|
NGM Biopharmaceuticals, Inc.
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to...
NGM Bio to Present at Two Upcoming Investor Conferences
June 07, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...